



## 89bio to Participate in the Leerink Partners Global Biopharma Conference

March 5, 2024

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings.

The webcast of the fireside chat will be accessible [here](#) and in the investor section of [89bio's website](#).

### About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. Pegozafermin has been granted Breakthrough Therapy Designation for the treatment of NASH with fibrosis from U.S. Food and Drug Administration (FDA). The company is headquartered in San Francisco. For more information, visit [www.89bio.com](http://www.89bio.com) or follow the company on LinkedIn.

### Investor Contact:

Annie Chang  
89bio, Inc.  
[investors@89bio.com](mailto:investors@89bio.com)

PJ Kelleher  
LifeSci Advisors, LLC  
+1-617-430-7579  
[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)

### Media Contact:

Sheryl Seapy  
Real Chemistry  
[sseapy@realchemistry.com](mailto:sseapy@realchemistry.com)